The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by ...

Explore the growing GLP-1 agonists market, driven by rising diabetes and obesity rates. Discover advancements in therapies like Tirzepatide and GZR18 ...

Lilly partners with API to launch ‘Obesity Gurukul’, a flagship continuing medical education program: Our Bureau, Bengaluru Monday, July 14, 2025, 15:20 Hrs [IST] Eli Lilly an ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite control and metabolic pathways, with pharmaceutical ...

New data and analyses presented at the American Diabetes Association’s annual meeting highlight the priorities for the next ...

This segment is sponsored by Eli Lilly and Company.Social media is flooded with advertisments for popular obestiy medications ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should ...

Eli Lilly reported impressive data at the recent American Diabetes Association ('ADA') conference. Its robust pipeline will ...

Obesity medications, once facing shortages, are now widely available. So how do consumers not get scammed into purchasing ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Eli Lilly (LLY 0.40%) and Novo Nordisk (NVO 1.97%) are two phenomenal growth stocks that investors probably can't go wrong ...

The weight-loss drug boom has dominated headlines for the last two years — but underneath the hype lies a major flaw in the ...